SNDX — Syndax Pharmaceuticals Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1395937 ·
Last close
$19.05
Market Cap
$1.69B
52W High
$25.24
52W Low
$16.66
ADV30
1,937,803
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 64,864,000 | 62,231,000 | -34,202,000 | -42,673,000 | 472,668,000 | 130,893,000 | 431,046,000 |
| Dec 2025 | 68,728,000 | 66,022,000 | -62,548,000 | -68,014,000 | 529,706,000 | 134,930,000 | 465,076,000 |
| Sep 2025 | 45,871,000 | 43,771,000 | -57,426,000 | -60,715,000 | 551,792,000 | 116,808,000 | 436,362,000 |
| Jun 2025 | 37,958,000 | 36,679,000 | -69,353,000 | -71,847,000 | 596,149,000 | 108,636,000 | 438,725,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-278,163,000
Investing CF
$234,284,000
Financing CF
$20,664,000
CapEx
$-56,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.79
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,549,253,000
Inventory
$34,948,000
Receivables
$60,693,000
ST Investments
$230,346,000
EBIT TTM
$-205,669,000
Pretax Income TTM
$-243,249,000
Interest Exp TTM
$37,580,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$217,174,000
EBITDA
$-223,768,000
Free Cash Flow
$-186,008,496
Enterprise Value
$1,710,244,352
Total Cash
$361,239,008
Total Debt
$345,360,000
Shares Out
88,610,027
Trailing EPS
$-2.79
Book Value
$0.47
ROE
-189.5%
ROA
-25.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 172,352,000 | -273,084,000 | -285,422,000 | 529,706,000 | 465,076,000 | — | -322,980,000 |
| Dec 2024 | 23,680,000 | -339,672,000 | -318,758,000 | 724,816,000 | 436,692,000 | — | -274,903,000 |
| Dec 2023 | 0 | -229,954,000 | -209,360,000 | 612,880,000 | 58,684,000 | — | -160,601,000 |
| Dec 2022 | 0 | -151,757,000 | -149,338,000 | 497,236,000 | 29,787,000 | — | -133,675,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.36
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $1.74B | $5.71 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.63B | $17.42 | — |
| ZYME | Zymeworks Inc. | $1.60B | $21.94 | — |
| BCAX | Bicara Therapeutics Inc. | $1.78B | $27.10 | — |
| DMRA | Damora Therapeutics, Inc. | $1.78B | $28.99 | — |
News headlines (Yahoo Finance, 1h cache)
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
2026-07-28 11:00 · Yahoo
Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?
2026-07-22 11:58 · Yahoo
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know
2026-07-17 16:00 · Yahoo
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
2026-07-14 20:02 · Yahoo
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
2026-07-14 13:55 · Yahoo
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
2026-07-14 12:00 · Yahoo
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-07-01 20:01 · Yahoo
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
2026-06-30 13:06 · Yahoo
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
2026-06-23 11:55 · Yahoo
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed
2026-06-13 12:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.